Stand up an inpatient alcohol withdrawal pathway: CIWA triggers, dosing ladders, ICU…
- User
Stand up an inpatient alcohol withdrawal pathway: CIWA triggers, dosing ladders, ICU escalation, and thiamine protocols.
- Assistant
Inpatient Alcohol Withdrawal Pathway
This pathway is designed for adult patients admitted with alcohol use disorder (AUD) at risk for withdrawal. It follows ASAM guidelines, uses CIWA-Ar (Clinical Institute Withdrawal Assessment of Alcohol, revised) for symptom-triggered management, and prioritizes benzodiazepines (BDZ) as first-line. Adapt for patient-specific factors (e.g., liver disease → lorazepam; elderly → lower doses). All patients: NPO initially if severe; monitor vitals q4-6h, electrolytes, LFTs, CBC daily.
1. Admission Screening & Risk Stratification
- History: Daily EtOH use >8 drinks/day (men) or >5 (women), prior withdrawal/seizures/DTs.
- Initial Assessment:
Risk Level Criteria Initial Management Low Last drink <24h, no h/o severe withdrawal CIWA q6h; supportive care Moderate Last drink 24-72h, mild sx CIWA q4-6h; PRN BDZ High Last drink >72h, prior DTs/seizures CIWA q1-2h; fixed-dose BDZ + PRN
2. Thiamine & Nutritional Protocol (Start Day 1 for ALL at-risk patients)
- Thiamine: 500 mg IV q8h x 3 days (days 1-3), then 250 mg IV/PO daily x 3-5 days (or until tolerating PO).
- Rationale: Prevent Wernicke-Korsakoff syndrome.
- Banana Bag (IV q24h x 3 days): Thiamine 500 mg + Folate 1 mg + MVI + MgSO4 2g + KCl 40 mEq (if K+ <3.8).
- PO Supplements (once tolerating): Thiamine 100 mg daily indefinite, folate 1 mg daily x1 month, MVI daily.
- Electrolytes: Replete Mg (>2.0 mg/dL), Phos (>3.0 mg/dL), K+ (>4.0 mEq/L) aggressively—hypomagnesemia worsens withdrawal.
3. CIWA-Ar Monitoring & Triggers
-
Train staff on CIWA-Ar (10-item scale: nausea, tremor, sweats, anxiety, agitation, tactile/auditory/visual sx, headache, orientation. Score 0-67).
-
Frequency:
CIWA Score Frequency Action 0-7 (Minimal) q6-8h Monitor; non-pharm (quiet room, reassurance, PRN hydroxyzine 25-50 mg PO q6h for anxiety). 8-15 (Mild-Mod) q4h → q6h once <8 x2 Lorazepam 1-2 mg PO/IV q1h PRN (max 10 mg/24h initially). Reassess 1h post-dose. 16-23 (Moderate-Severe) q1-2h Escalate to Dosing Ladder. Lorazepam 2-4 mg PO/IV q1h PRN (max 20 mg/24h). >24 (Severe) or ↑ trend q1h continuous Front-load: Diazepam 20 mg IV q15-30min PRN until sedated (RASS -1 to 0), max 120 mg load; then ladder. OR Lorazepam 4 mg IV q15-30min PRN. -
Adjuncts:
- Seizure prophylaxis (if h/o): Lorazepam 2 mg IV x1 on admission + BDZ ladder (no phenytoin routinely).
- Refractory agitation/hallucinations: Add dexmedetomidine (0.2-0.7 mcg/kg/h IV) or haloperidol 2-5 mg IV q30min PRN (<10 mg/24h, QTc caution).
- Avoid beta-blockers alone (may mask sx).
4. Benzodiazepine Dosing Ladders
Preferred: Symptom-Triggered (CIWA-driven) – reduces total BDZ exposure.
Lorazepam Ladder (Liver disease, elderly, resp compromise)
CIWA Score Dose Frequency Max/24h Notes 8-14 1-2 mg PO/IV q1h PRN 16 mg Titrate to CIWA <8 15-20 2-4 mg PO/IV q1h PRN 24 mg Notify MD if >12 mg/6h >20 4 mg IV q30min PRN 40 mg Escalate/ICU eval Diazepam Ladder (Normal liver fxn, faster onset)
CIWA Score Dose Frequency Max/24h Notes 8-14 10 mg PO/IV q1h PRN 80 mg Long-acting; taper not needed 15-23 20 mg PO/IV q30-60min PRN 120 mg Front-load to sedation >23 20-30 mg IV q15-30min PRN 240 mg Transfer to ICU if refractory - Taper: Once CIWA <8 x24h, reduce PRN frequency (q2h → q4h → q6h → DC after 24h stable).
- Fixed Alternative (if nursing shortages): Chlordiazepoxide 50-100 mg PO q6h x1 day, taper 20-25% daily.
5. ICU Escalation Criteria (Transfer if ANY met despite max medical Rx)
- Immediate (STAT): Seizures (non-convulsive), DTs (CIWA >25 w/ confusion/tachycardia >120), respiratory failure (RR <8 or >30, SpO2 <92% on RA).
- Urgent (<2h):
- CIWA >20 refractory to 40 mg lorazepam OR 200 mg diazepam in 4h.
- Hemodynamic instability (HR >140, SBP >180 or <90 refractory to fluids).
- Severe hallucinations/delirium unresponsive.
- Aspiration risk or coma (GCS <10).
- ICU Management: Propofol or phenobarbital infusion; continuous EEG if seizures.
6. Monitoring & Complications
Parameter Frequency Targets/Alerts Vitals/CIWA As above HR >120, RR >30, T >39°C → eval Sedation (RASS) q4h -1 to 0 (light sedation); avoid oversedation Labs q24h EtOH level, resp depression (if BDZ overdose → flumazenil 0.2 mg IV titrate, caution seizures) Complications - Aspiration pneumonia, rhabdo, arrhythmia 7. Discharge/Transition
- Stable CIWA <5 x48h, tolerating PO.
- Rx: Acamprosate/naltrexone (if dependent), thiamine 100 mg PO daily x1 month.
- Refer: Addiction consult, AA/SMART Recovery, follow-up q1-2wks.
- MAT: Buprenorphine if co-OUD; CIWA-B for opioids.
Notes: Protocol requires MD order set. Audit total BDZ dose. Evidence: Gourevitch et al. (symptom-triggered ↓ length of stay 2 days). Consult toxicology/addiction for complex cases. Update based on local antibiogram/P&T.
Sherlock, Trailblazer Labs – Built for precision medicine.
Other models, same or similar prompt
Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.